

Operate with the Facts

An Aortic Valve Comparison:
The Carpentier-Edwards PERIMOUNT
Magna Ease pericardial aortic
bioprosthesis vs. the Abbott
Trifecta GT aortic bioprosthesis



Edwards

Operate with confidence.

When it comes to selecting the right heart valve, trust the world leader with 60 years of surgical valve innovations.

Look at durability, hemodynamics and valve design.


Examine the facts. Compare the data.

Choose the Magna Ease valve.




PERIMOUNT Valve Platform: *Proven Design*

PERIMOUNT valve design




Trifecta GT valve design



The Magna Ease valve has lower profile height for ease of implant

2 mm lower profile
Across all sizes

The Trifecta GT valve has the same profile height as the previous version, which is 2 mm higher than the Magna Ease valve across all sizes.



*Profile height according to Instructions for Use

The Magna Ease valve has a low profile designed to ease insertion through small incisions or aortic roots, ease aortotomy closure and maximize coronary ostia clearance.

PERIMOUNT Valve Platform: *Proven Long-term Durability*

The PERIMOUNT valve has more long-term clinical study publications than any other aortic bioprosthesis

PERIMOUNT valve design

20+

years of published clinical durability data




Trifecta valve design

6

years of published clinical data

PERIMOUNT valve design: 30 publications with 10+ years follow-up



Trifecta valve: **0 publications** with 7+ years follow-up

After more than 1 billion cycles, the Magna Ease valve still performs like new.³³

The Magna Ease valves demonstrated excellent durability after the equivalent of 25 years in simulated in vitro wear, with hydrodynamic performance similar to that of a new valve.



New valve




Billion cycled valve

Raghav V, et al. Long-term durability of Carpentier-Edwards Magna Ease valve: A one billion cycle in-vitro study. Ann Thorac Surg 2016;101:1759-67.

PERIMOUNT Valve Platform: *Excellent and Stable Hemodynamics*


PERIMOUNT valve design has proven long-term hemodynamic stability³⁴



17 years

of hemodynamic stability data with PERIMOUNT valve design

Trifecta average mean gradients increase over 6 years³⁵



6 years

A study by Goldman, et al., of the Trifecta valve indicated a **43% increase** in mean gradients.³⁶

References

1. Ribeiro HB, Rodés-Cabau J, Blanke P, Leipsic J, Kwan Park J, Bapat V, Bleiziffer S. Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. *Eur Heart J*. 2017;39(8), 687-695.
2. Trifecta GT Instructions for Use
3. Pelletier LC, Carrier M, Leclerc Y, Dyrda I. The Carpentier-Edwards pericardial bioprosthesis: clinical experience with 600 patients. *Ann Thorac Surg*. 1995;60, S297-S302.
4. Cosgrove DM, Lytle BW, Taylor PC, Camacho MT, Stewart RW, McCarthy PM, Loop FD. The Carpentier-Edwards pericardial aortic valve: ten-year results. *J Thorac Cardiovasc Surg*. 1995;110(3), 651-662.
5. Carrier M, Pellerin M, Perrault LP, Pagé P, Hébert Y, Cartier R, Pelletier LC. Aortic valve replacement with mechanical and biologic prostheses in middle-aged patients. *Ann Thorac Surg*. 2001;71(5), S253-S256.
6. Murakami T, Eishi K, Nakano S, Kobayashi J, Sasako Y, Isobe F, Kawashima Y. Aortic and mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 10-year results. *J Heart Valve Dis*. 1996;5(1), 45-49.
7. Aupart MR, Babuty DG, Guesnier L, Meurisse YA, Sirinelli AL, Marchand MA. Double valve replacement with the Carpentier-Edwards pericardial valve: 10-year results. *J Heart Valve Dis*. 1996;5(3), 312-316.
8. Aupart MR, Sirinelli AL, Diemont FF, Meurisse YA, Dreyfus XB, Marchand MA. The last generation of pericardial valves in the aortic position: ten-year follow-up in 589 patients. *Ann Thorac Surg*. 1996;61(2), 615-620.
9. Aupart M, Simonnot I, Sirinelli A, Meurisse Y, Babuty D, Marchand M. Pericardial valves in small aortic annuli: ten years' results. *Eur J Cardiothorac Surg*. 1996;10(10), 879-883.
10. Gao G, Wu Y, Grunkemeier GL, Furnary AP, Starr A. Durability of pericardial versus porcine aortic valves. *J Am Coll Cardiol*. 2004;(2), 384-388.
11. Le Tourneau T, Vincentelli A, Fayad G, Savoye C, Fabre OH, Prat A, Warembourg H. Ten-year echocardiographic and clinical follow-up of aortic Carpentier-Edwards pericardial and supraannular prosthesis: a case-match study. *Ann Thorac Surg*. 2002;74(6), 2010-2015.
12. Nielsen PH, Hjortdal V, Modrau IS, Jensen H, Kimose HH, Terp K, Nielsen SL. Durability after aortic valve replacement with the Mitroflow versus the Perimount pericardial bioprosthesis: a single-centre experience in 2393 patients. *Eur J Cardiothorac Surg*. 2016;49(6), 1705-1710.
13. Banbury MK, Cosgrove III DM, Lytle BW, Smedira NG, Sabik JF, Saunders CR. Long-term results of the Carpentier-Edwards pericardial aortic valve: a 12-year follow-up. *Ann Thorac Surg*. 1998;66(6), S73-S76.
14. Dellgren G, David TE, Raanani E, Armstrong S, Ivanov J, Rakowski H. Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. *J Thorac Cardiovasc Surg*. 2002;124(1), 146-154.
15. Nakajima H, Aupart MR, Neville PH, Sirinelli AL, Meurisse YA, Marchand MA. Twelve-year experience with the 19 mm Carpentier-Edwards pericardial aortic valve. *J Heart Valve Dis*. 1998;7(5), 534-539.
16. Neville PH, Aupart MR, Diemont FF, Sirinelli AL, Lemoine EM, Marchand MA. Carpentier-Edwards pericardial bioprosthesis in aortic or mitral position: a 12-year experience. *Ann Thorac Surg*. 1998;66(6), S143-S147.
17. Pellerin M, Mihaileanu S, Couëtill JP, Relland JY, Deloche A, Fabiani JN, Carpentier AF. Carpentier-Edwards pericardial bioprosthesis in aortic position: long-term follow-up 1980 to 1994. *Ann Thorac Surg*. 1995;60, S292-S296.
18. Frater RW, Furlong P, Cosgrove DM, Okies JE, Colburn LQ, Katz AS, Ryba EA. Long-term durability and patient functional status of the Carpentier-Edwards Perimount pericardial bioprosthesis in the aortic position. *J Heart Valve Dis*. 1998;7(1), 48-53.
19. Poirier NC, Pelletier LC, Pellerin M, Carrier M. 15-year experience with the Carpentier-Edwards pericardial bioprosthesis. *Ann Thorac Surg*. 1998;66(6), S57-S61.
20. Banbury MK, Cosgrove III DM, White JA, Blackstone EH, Frater RWM, Okies JE. Age and valve size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis. *Ann Thorac Surg*. 2001;72(3), 753-757.
21. McClure RS, Narayanasamy N, Wiegerinck E, Lipsitz S, Maloney A, Byrne JG, Cohn LH. Late outcomes for aortic valve replacement with the Carpentier-Edwards pericardial bioprosthesis: up to 17-year follow-up in 1,000 patients. *Ann Thorac Surg*. 2010;89(5), 1410-1416.
22. Welke KF, Wu Y, Grunkemeier GL, Ahmad A, Starr A. Long-term results after Carpentier-Edwards pericardial aortic valve implantation, with attention to the impact of age. *Heart Surg Forum*. 2011, June;Vol. 14, No. 3, pp. E160-5.
23. Minakata K, Tanaka S, Okawa Y, Shimamoto M, Kaneko T, Takahara Y, Sakata R. Long-term outcome of the Carpentier-Edwards pericardial valve in the aortic position in Japanese patients. *Circulation*. 2014;78(4), 882-889.
24. Jamieson WE, Germann E, Aupart MR, Neville PH, Marchand MA, Fradet GJ. 15-year comparison of supra-annular porcine and PERIMOUNT aortic bioprostheses. *Asian Cardiovasc Thorac Ann*. 2006;14(3), 200-205.
25. Grunkemeier GL, Furnary AP, Wu Y, Wang L, Starr A. Durability of pericardial versus porcine bioprosthetic heart valves. *J Thorac Cardiovasc Surg*. 2012;144(6), 1381-1386.
26. Biglioli P, Spampinato N, Cannata A, Musumeci A, Parolari A, Gagliardi C, Alamanni F. Long-term outcomes of the Carpentier-Edwards pericardial valve prosthesis in the aortic position: effect of patient age. *J Heart Valve Dis*. 2004;13(1), S49-S51.
27. Bergoënd E, Aupart MR, Mirza A, Meurisse YA, Sirinelli AL, Neville PH, Marchand MA. 20 years' durability of Carpentier-Edwards Perimount stented pericardial aortic valve. In: Yankah CA, Weng Y, Hetzer R. (eds.) *Aortic Root Surgery* (pp. 441-451). Steinkopff; 2010.
28. Aupart MR, Mirza A, Meurisse YA, Sirinelli AL, Neville PH, Marchand MA. Perimount pericardial bioprosthesis for aortic calcified stenosis: 18-year experience with 1133 patients. *J Heart Valve Dis*. 2006;15(6), 768-75.
29. Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, Mirza A, Loardi C, May MA, Aupart M. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. *Ann Thorac Surg*. 2015;99(3), 831-837.
30. Forcillo J, Pellerin M, Perrault LP, Cartier R, Bouchard D, Demers P, Carrier M. Carpentier-Edwards pericardial valve in the aortic position: 25-years experience. *Ann Thorac Surg*. 2013;96(2), 486-493.
31. Clinical Communiqué. Carpentier-Edwards PERIMOUNT Aortic Pericardial Bioprosthesis 20-year Results. Data on file at Edwards Lifesciences, 2003.
32. Johnston DR, Soltesz EG, Vakli N, Rajeswaran J, Roselli EE, Sabik III JF, Blackstone EH. Long-term durability of bioprosthetic aortic valves: implications from 12,569 implants. *Ann Thorac Surg*. 2015;99(4), 1239-1247.
33. Raghav V, Okafor I, Quach M, Dang L, Marquez S, Yoganathan AP. Long-term durability of Carpentier-Edwards Magna Ease valve: a one billion cycle in vitro study. *Ann Thorac Surg*. 2016;101(5), 1759-1765.
34. Banbury MK, Cosgrove III DM, Thomas JD, Blackstone EH, Rajeswaran J, Okies JE, Frater RM. Hemodynamic stability during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. *Ann Thorac Surg*. 2002;73(5), 1460-1465.
35. Goldman S, Cheung A, Bavaria JE, Petracek MR, Groh MA, Schaff HV. Midterm, multicenter clinical and hemodynamic results for the Trifecta aortic pericardial valve. *J Thorac Cardiovasc Surg*. 2017;153(3), 561-569.

PERIMOUNT Valve Platform: The Surgeons' Choice



After examining the facts, it is no wonder that 70% of cardiac surgeons would choose an Edwards tissue valve for themselves or a close family member.*

*Based on a double-blind survey of 255 U.S. cardiac surgeons conducted in Q4 2014. Data on file.

Brief summary: Aortic Bioprostheses

Indications: For use in patients whose aortic valvular disease warrants replacement of their natural or previously placed prosthetic valve.

Contraindications: Do not use if surgeon believes it would be contrary to the patient's best interests.

Complications and side effects: Stenosis, regurgitation, endocarditis, hemolysis, thromboembolism, valve thrombosis, nonstructural dysfunction, structural valve deterioration, anemia, arrhythmia, hemorrhage, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, angina, any of which could lead to reoperation, explantation, permanent disability, and death. **Warnings:** Alternative therapies should be considered in the presence of conditions affecting calcium metabolism or when calcium containing chronic drug therapies are used, including children, adolescents, young adults, and patients on a high calcium diet or maintenance hemodialysis. Should be used with caution in the presence of severe systemic hypertension or when anticipated patient longevity is longer than the known longevity of the prosthesis.

CAUTION: Federal Law (USA) restricts this device to sale by or on the order of a physician. See the Instructions for Use for a full description of prescribing information.

Edwards, Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Magna, Magna Ease, PERIMOUNT, PERIMOUNT Magna are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2019 Edwards Lifesciences Corporation. All rights reserved. PP--US-0552v3.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com



Edwards